Ono Pharmaceutical Co., Ltd.

— Pilot & first-year Platinum Program has provided eight companies pre-seed funding totaling $3.5 million, lab space, and mentorship and is now offering drug discovery and corporate advisory services from new sponsors Alloy Therapeutics, Goodwin, and van den Boom & Associates — CAMBRIDGE, Mass., Oct. 30, 2024 /PRNewswire/ -- Mission BioCapital (MBC) announced today the first eight investments supported by the Platinum Program, a competitive process managed by MBC to accelerate the launch and initial development of high-potential life sciences start-up companies by providing funding, global laboratory space, expert mentorship, and discovery services. The following six investments were made through the 2023 Mission BioCapital Platinum Program: Babylon Biosciences (San Francisco) is focused on discovering and developing small-molecule therapeutics to treat Alzheimer's disease. Bullseye Biosciences (Cambridge, MA) is revolutionizing drug development through robotics and evolution to target challenging drivers of cardiometabolic inflammatory diseases and oncology. Cloverleaf Bio (New Haven) is a Yale spinout developing a new platform of engineered tRNA therapeutics to improve patient outcomes in oncology. Nucyrna Therapeutics (Cambridge, MA) aims to refine RNA-targeting therapeutics based on a novel oligonucleotide platform, with an initial focus on CNS diseases. Umlaut.Bio (Heidelberg, Germany), a spinout of the European Molecule Biology Laboratory (EMBL), is pursuing tRNA targets for treatment of cancer and immunological diseases. Velocity Bio (San Carlos, CA) is a Stanford University spinout developing high-throughput platforms capable of selectivity-first allosteric drug discovery for under-drugged human enzymes implicated in devastating diseases. Mission BioCapital's pilot Platinum Program in 2022 resulted in the following two investments: TippingPoint Biosciences (San Francisco) is a UCSF spinout developing a drug discovery platform to identify treatments for diseases caused by defects in DNA packaging, including several hard-to-treat cancers. Integrated Biosciences (San Carlos, CA) is combining synthetic biology and machine learning to discover small-molecule therapeutics targeting aging and age-related diseases. Winners to date have received a combined $3,500,000 in pre-seed capital, a lab bench in one of Mission BioCapital's affiliated incubators located in 14 markets across in the U.S. and Europe, and strategic scientific and business development mentorship provided by experts from the program's founding sponsors, Eli Lilly and Company (Lilly), Ono Venture Investment (ONO), and MBC. "Now in its third year, we have been so pleased with the number of high-potential, visionary life sciences founders that have applied to the competition from around the globe," said Jennifer Griffin, Ph.D., Partner, Mission BioCapital. "We are proud to support early-stage innovation with critical capital, turnkey infrastructure, and strategic mentoring alongside our partners, Lilly and ONO. We thank them for their shared vision and resources that have enabled the program to scale its impact for biotech founders." Applications for 2023 were submitted from around the world, including 12 countries and 31 U.S. states. A panel of judges comprising the MBC investment team and senior executives from Lilly and ONO reviewed the submissions and identified 15 finalists to pitch to the partnership, which selected six companies developing novel solutions for patients. Mission BioCapital continued to scale the Platinum Program's impact in 2024 by introducing "preferred service" sponsors, welcoming new partners Alloy Therapeutics, Goodwin Procter LLP, and van den Boom & Associates, which have committed to offering complementary drug discovery services, general counsel, and accounting services, respectively, to future winners. "It's extremely gratifying to watch our Platinum Program grow, thanks in large part to our sponsors," said Steve Tregay, Ph.D., Managing General Partner, Mission BioCapital. "Our second annual competition tripled the seed funding amounts while greatly expanding the program's geographic reach to find new talent and innovations outside of the major San Francisco and Boston biotechnology hubs. The addition of the new sponsors further augments the program by facilitating access to services that are critical for early-stage biotech companies." "Accelerating innovation by partnering our drug discovery expertise with the novel ideas of early-stage biotech companies is at the heart of what we do," said Errik Anderson, CEO and Founder of Alloy Therapeutics. "We're thrilled to partner with Mission BioCapital to enable biotech founders through the Platinum Program, providing support for the critical initial work to de-risk a company's lead candidate." About the Mission BioCapital Platinum Program Mission BioCapital (MBC) established the Platinum Program in 2022 to enable entrepreneurs with breakthrough technologies from diverse backgrounds to quickly launch new companies. Platinum Program winners receive guaranteed laboratory space at MBC's partner incubators in the U.S. and Europe, access to world-class experts, lead candidate-enabling drug discovery services, and seed capital to quickly develop scientific data needed to obtain subsequent funding rounds. The program invites innovators from around the world, including academic scientists, to submit breakthrough biomedical innovations that have the potential to advance patient care. In its first two years, the Mission BioCapital Platinum Program has awarded a total of $3.5 million, incubator space, and business mentoring to eight life sciences companies located in two countries and three U.S. states. For more information about the Mission BioCapital Platinum Program, please visit . About Mission BioCapital Mission BioCapital is a venture capital firm focused on making pivotal early-stage investments in life sciences companies. We support our portfolio companies through a unique combination of shared lab space, capital investment, and access to strategic partners. With offices in the nation's leading life sciences clusters in Cambridge, MA and San Francisco, Mission BioCapital is dedicated to helping entrepreneurial scientists build successful companies, from idea to exit. Learn more at missionbiocapital.com. Contact: Mary Moynihan M2Friend Biocommunications +1 (802) 951-9600 [email protected] SOURCE Mission BioCapital WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

JAK inhibitors are a class of medications that work by blocking Janus kinases (JAKs), enzymes that are involved in the signaling pathways of various cytokines and growth factors. JAK inhibitors offer a more targeted approach to treating immune-mediated diseases compared to traditional therapies like corticosteroids or conventional immunosuppressants; this specificity reduces side effects and increases efficacy and is a major driver for the demand for JAK inhibitors. LAS VEGAS, Oct. 22, 2024 /PRNewswire/ -- DelveInsight's ' JAK Inhibitors Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline JAK inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the JAK inhibitors pipeline domain. Key Takeaways from the JAK Inhibitors Pipeline Report DelveInsight's JAK inhibitors pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline JAK inhibitors. Key JAK inhibitors companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma, Esker Therapeutics, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical and others are evaluating new JAK Inhibitors drugs to improve the treatment landscape. Promising pipeline JAK inhibitors such as Povorcitinib, CPL409116, ATI-2138, SDC 1802, AZD 4604, INCB-160058, Research programme: JAK2 inhibitors, Ritlecitinib, Momelotinib, DZD4205, ATI 2138, CPL 409116, Itacitinib, Ivarmacitinib, ESK 001, Repotrectinib, Rovadicitinib, and others are under different phases of JAK inhibitors clinical trials. In October 2024, Pelabresib in combination with ruxolitinib showed benefit in treating patients with JAK Inhibitor-Naïve Myelofibrosis significantly reduced splenomegaly, and improved anemia that has not been previously treated with Janus kinase inhibitors (JAKis). In September 2024, Eli Lilly and Company and EVA Pharma announced that the companies have agreed to expand access to baricitinib to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. In May 2024, Ajax Therapeutics, Inc., announced that it had received clearance for its Investigational New Drug application from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical study of AJ1–11095, a first-in-class Type II JAK2 inhibitor, for the treatment of patients with myelofibrosis. In February 2024, Novartis announced that it intends to acquire MorphoSys. The acquisition, which was unanimously approved by the boards of both Novartis and MorphoSys, is expected to close in the first half of 2024, subject to customary closing conditions. In January 2024, NS Pharma received orphan drug designation (ODD) from the European Commission (EC) for NS-229, which is being developed to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease. In December 2023, Sun Pharmaceuticals Inc. announced that it has entered a licensing agreement with Aclaris Therapeutics Inc., the company announced in a regulatory filing. Under the agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma's JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). Request a sample and discover the recent advances in JAK inhibitors drugs @ JAK Inhibitors Pipeline Report The JAK inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage JAK inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the JAK inhibitors clinical trial landscape. JAK Inhibitors Overview Janus kinase (JAK) inhibitors are a class of medications designed to interfere with the activity of the Janus kinase family of enzymes, which play a crucial role in the signaling pathways of immune responses. These enzymes are key mediators in transmitting signals from cytokines and growth factors, which regulate blood cell production and immune system function. By blocking these signals, JAK inhibitors help to control the overactive immune response seen in several inflammatory and autoimmune diseases. They have shown significant efficacy in treating conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, among others. The most common JAK inhibitors include tofacitinib, baricitinib, and upadacitinib, which are administered orally. Beyond their role in autoimmune diseases, JAK inhibitors are also being explored for use in treating certain cancers and myeloproliferative disorders, where abnormal JAK signaling contributes to uncontrolled cell growth. In diseases like myelofibrosis and polycythemia vera, JAK inhibitors can help reduce symptoms and improve quality of life. However, there are potential side effects associated with their use, including increased susceptibility to infections, blood clots, and cardiovascular risks, given their impact on the immune system. As research continues, the therapeutic potential of JAK inhibitors is expanding, offering new hope for patients with difficult-to-treat conditions. Find out more about JAK inhibitors drugs @ JAK Inhibitors Analysis A snapshot of the Pipeline JAK Inhibitors Drugs mentioned in the report: Learn more about the emerging JAK inhibitors @ JAK Inhibitors Clinical Trials JAK Inhibitors Therapeutics Assessment The JAK inhibitors pipeline report proffers an integral view of the emerging JAK inhibitors segmented by stage, product type, molecule type, and route of administration. Scope of the JAK Inhibitors Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Key JAK Inhibitors Companies: Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, AstraZeneca, Incyte Corporation, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Celon Pharma, Incyte Corporation, Arcutis Biotherapeutics/Reistone Biopharma, Esker Therapeutics, Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical, and others. Key JAK Inhibitors Pipeline Therapies: Povorcitinib, CPL409116, ATI-2138, SDC 1802, AZD 4604, INCB-160058, Research programme: JAK2 inhibitors, Ritlecitinib, Momelotinib, DZD4205, ATI 2138, CPL 409116, Itacitinib, Ivarmacitinib, ESK 001, Repotrectinib, Rovadicitinib, and others. Dive deep into rich insights for new JAK inhibitors, visit @ JAK Inhibitors Drugs Table of Contents For further information on the JAK inhibitors pipeline therapeutics, reach out @ JAK Inhibitors Therapeutics Related Reports JAK Inhibitors Market JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Eli Lilly and Company, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Incyte Corporation, Kartos Therapeutics, Inc., Dompé Farmaceutici S.p.A, Sanofi, Kiniksa Pharmaceuticals, Ltd., Celgene, Abivax S.A., Telios Pharma, Inc., AstraZeneca, Karyopharm Therapeutics Inc, TWi Biotechnology, Inc., Geron Corporation, Ajax Therapeutics, Inc., among others. JAK Inhibitors Competitive Landscape JAK Inhibitors Competitive Landscape – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others. KRAS Inhibitors Market KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio , among others. PD/L-1 Inhibitors Market PD/L-1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD/L-1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Ono Pharmaceutical has inked a license agreement with LigaChem Biosciences (LCB) for LCB97, a pre-clinical antibody-drug conjugate (ADC) aimed at treating solid tumors. The Osaka-based company also announced a research collaboration and license agreement to generate new ADC candidates using LCB’s ConjuAll ADC platform. LCB97, which targets the L1 cell adhesion molecule (L1CAM), has shown strong anti-tumor effects in preclinical studies. Under the agreement, Ono secures exclusive global rights to develop, manufacture, and commercialize LCB97 for solid tumors. The deal includes upfront and milestone payments to LCB, potentially totaling up to $700 million, along with tiered royalties based on net sales. Additionally, the two companies will collaborate on developing further ADC candidates, giving Ono exclusive global rights to any new therapies targeting multiple solid tumors. With a market poised to reach over $13 billion by 2026, today’s ADCs may have finally earned their permanent place on the industry stage. In our three-part series, we cover the trajectory of cancer-fighting ADCs in the pharma industry, including the modality’s history, obstacles and success stories.